Keros Therapeutics Q1 2023 Earnings Report $11.38 -0.55 (-4.61%) As of 03/7/2025 04:00 PM Eastern Earnings HistoryForecast Keros Therapeutics EPS ResultsActual EPS-$1.26Consensus EPS -$1.14Beat/MissMissed by -$0.12One Year Ago EPS-$1.01Keros Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.22 millionBeat/MissN/AYoY Revenue GrowthN/AKeros Therapeutics Announcement DetailsQuarterQ1 2023Date5/4/2023TimeAfter Market ClosesConference Call ResourcesPress ReleaseKROS Earnings HistoryPowered by Remove Ads Keros Therapeutics Earnings HeadlinesKeros Therapeutics, Inc. (NASDAQ:KROS) Receives $42.33 Average Target Price from AnalystsMarch 6, 2025 | americanbankingnews.comHC Wainwright Issues Optimistic Outlook for KROS EarningsMarch 4, 2025 | americanbankingnews.comAI Shock Coming on March 18? Prepare NowIf you’re worried about all the recent volatility in the market… Or if you have any money in AI stocks… You MUST prepare for this AI event scheduled for March 18th at 1 p.m. ET.March 10, 2025 | Brownstone Research (Ad)What is William Blair's Estimate for KROS Q1 Earnings?March 3, 2025 | americanbankingnews.comBank of America Securities Remains a Buy on Keros Therapeutics (KROS)March 2, 2025 | markets.businessinsider.comQ2 Earnings Forecast for KROS Issued By Leerink PartnrsMarch 2, 2025 | americanbankingnews.comSee More Keros Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Keros Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your email. Email Address About Keros TherapeuticsKeros Therapeutics (NASDAQ:KROS), a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.View Keros Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Upcoming Earnings Adobe (3/12/2025)PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (4/1/2025)Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
